<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase (MAPK) and <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase/AKT signaling pathways interact at multiple nodes in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, including at mTOR complexes, suggesting an increased likelihood of redundancy and innate resistance to any therapeutic effects of single pathway inhibition </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the therapeutic effects of combining the MAPK extracellular signal-regulated kinase (MEK)1/2 inhibitor selumetinib (AZD6244) with the dual mTORC1 and mTORC2 inhibitor (AZD8055) </plain></SENT>
<SENT sid="2" pm="."><plain>Concurrent dosing in <z:mp ids='MP_0003815'>nude</z:mp> mouse <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> of human <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp> (<z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancers</z:e>) and colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> was well tolerated and produced increased antitumor efficacy relative to the respective monotherapies </plain></SENT>
<SENT sid="3" pm="."><plain>Pharmacodynamic analysis documented reciprocal pathway inhibition associated with <z:mp ids='MP_0006042'>increased apoptosis</z:mp> and <z:chebi fb="3" ids="33173">Bim</z:chebi> expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue from the combination group, where key genes such as DUSP6 that are under MEK functional control were also modulated </plain></SENT>
<SENT sid="4" pm="."><plain>Our work offers a strong rationale to combine selumetinib and AZD8055 in clinical trials as an attractive therapeutic strategy </plain></SENT>
</text></document>